Progyny (PGNY) Drew Fresh Attention After Its Outlook, Is It 25% Below Fair Value?

Progyny (PGNY) has come into focus after recent coverage highlighted its liquidity, operational efficiency and growth profile, following Q2 2026 revenue growth of 5.3% and full year revenue expectations of US$1.36b to US$1.385b.

See our latest analysis for Progyny.

Progyny’s recent Q2 update and revenue outlook appear to have drawn fresh attention, even as the 30 day share price return is down 18.46% and the year to date share price return is down 1.19%, while the 1 year total shareholder return is up 9.91%.

If you are looking beyond Progyny and want to see what else is moving, this is a good moment to scan for other healthcare focused AI opportunities through the 41 healthcare AI stocks.

Progyny’s share price has pulled back over the past month, even as revenue guidance points to continued growth. Has the recent drop already reflected most of the risk, or is much of the potential upside already included in the current price?

Most Popular Narrative: 24.8% Undervalued

Progyny’s most followed narrative points to a fair value of $33.82 compared with the last close of $25.43, which implies a sizeable valuation gap that rests on specific growth and profitability assumptions.

Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross-sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.

Read the complete narrative. Read the complete narrative.

Want to see what has to happen for that fair value to add up? The narrative leans on steadier revenue growth, rising margins and a lower future earnings multiple than today. The exact mix of those levers may surprise you.

Result: Fair Value of $33.82 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Progyny’s story still carries risk, particularly if employer cost controls curb demand for fertility and women’s health benefits or if new competitors pressure pricing and margins.

Find out about the key risks to this Progyny narrative.

Next Steps

With Progyny’s mix of risks and rewards in mind, this is a good time to review the numbers yourself and decide how you feel about the story. To see the brighter points that investors are focused on, take a closer look at the 5 key rewards.

Looking for more investment ideas beyond Progyny?

If Progyny has you thinking more broadly about opportunities, do not stop here. Use the Simply Wall St Screener to spot other stocks that could suit your approach.

• Target potential mispricings by scanning a curated set of undervalued opportunities through the 48 high quality undervalued stocks.
• Strengthen your focus on financial resilience by reviewing companies highlighted in the solid balance sheet and fundamentals stocks screener (50 results).
• Get ahead of the crowd by checking companies that feature in the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com